Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Post by biorunon Oct 04, 2022 8:40am
320 Views
Post# 35003509

Irrational meets rational

Irrational meets rational

Time to decide. Bottom feeders are ready to take your shares and sell them back to you at an elevated price.

Objectively:

1. Net new global deal with Abbvie worth at minimum the current valuation alone, and likely 2x that. The company has a clear path to profitability. I have zero reason to doubt this. It will be the cash stream that funds and supports all the scientific possibilities and bring this to ultimate buyout.

2. There are indications that this year brings in a new CEO. At this point, I would say this alone would bring a significant bump in valuation.

3. Pets, anti-aging, and anti-viral are big hitter files that stand a reasonable chance to be positioned for massive success, maybe in the near term. I see at least two recent like scenarios where next day valuation is 10 fold higher on a single deal or development event.

4. Scientific capacity is expected to get an important boost with the independent review. There looks to be a conscious shift towards higher paying pharma vs cosmetic. The science there is absolutely without a doubt world class.

My goal is to exit gracefully from this stock once the aforementioned is realized. I will let you know when I do.

Unless there is something extraordinary to talk about, its time I give this a break and let you guys figure it out on your own.

I have said what I need to say, and I am tired of trying to convince all folks in the boat that dry land is coming. 

I can see the birds in the sky, and that is the first indicator its coming.

GLTA and do your own diligence before investing, or divesting.

Biorun

Trading opening price bid/ask 13.5

<< Previous
Bullboard Posts
Next >>